Long-Acting Reversible Contraceptives Not Linked to Increased STIs Among Teens
The risk of acquiring a sexually transmitted infection (STI) is not higher among adolescents using long-acting reversible contraceptives.
Contraception
FDA Approves New Contraceptive Patch
The FDA has approved Twirla (levonorgestrel and ethinyl estradiol) transdermal system (Agile Therapeutics) as a method of contraception for use in women of reproductive potential with a body mass index (BMI) <30kg/m2 for whom a combined hormonal contraceptive is appropriate.
Nutrition, Stress, Environment and Their Association With Acne
Nutrition, pollution, stress, and harsh skin care — climate and sun exposure, too — may be the most frequent contributing factors to acne, according to a large, international study.
Contraceptive Vaginal Ring Associated With Significantly Elevated Inflammatory Responses
Compared with injectable contraceptive norethisterone enanthate and combined oral contraceptive pills, contraceptive vaginal ring lowered cervical frequencies of Th17 cells, which may affect HIV risk stratification.
Hormonal vs Nonhormonal Contraception and Seizure Frequency in Epilepsy
Compared to nonhormonal contraception, hormonal contraception appears to pose a greater risk for increased seizure frequency in women with epilepsy.
FDA Approves First Generic Version of Contraceptive Vaginal Ring
The vaginal ring releases on average 0.12mg/d of etonogestrel, a progestin, and 0.015mg/d of ethinyl estradiol, an estrogen.
Few Women With Chronic Health Issues Use Reliable Birth Control
One in three women of reproductive age have a chronic condition that could compromise their health or lead to adverse outcomes during pregnancy, yet few use the most effective forms of contraception.
Adolescent Girls Using Oral Contraceptives Have Higher Self-Reported Depressive Symptoms
Symptoms of depression are associated with oral contraceptive use in 16-year-old girls compared with adolescents and young women up to 25 years of age.
FDA Approves a Levonorgestrel-Releasing IUD for Pregnancy Prevention for Up to 6 Years
The FDA has approved the use of Liletta (levonorgestrel-releasing intrauterine system; Allergan and Medicines360) for the prevention of pregnancy for up to 6 years. Previously, the progestin-containing intrauterine device was indicated for up to 5 years of use.
Levonorgestrel-Based IUD sNDA Seeks to Extend Contraceptive Use for Up to 6 Years
Bayer announced the submission of a supplemental New Drug Application to the Food and Drug Administration (FDA) for the intrauterine device.
Next post in Androgen and Reproductive Disorders
